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ABSTRACT 
 
The cognitive symptoms observed in schizophrenia are highly prevalent and predictive of patient 
functional outcome but are not usually alleviated by conventional antipsychotics. In a recent pilot 
study, sodium nitroprusside (SNP), a nitric oxide donor, was identified as a promising adjunct 
treatment to reduce the working memory impairments experienced by schizophrenia patients.  
Adjunctive SNP has also been reported to decrease the positive and negative symptoms 
experienced by patients for weeks following a single administration.  The mechanisms 
underlying these changes and the areas of cognition affected remain largely unknown.  
Therefore, it is of interest to examine the effects of SNP using a rodent model of schizophrenia 
that has demonstrated predictive validity.  The aim of the present experiment was to explore the 
effects of SNP on the acute MK-801 rodent model of schizophrenia using a highly translatable 
task in order to establish its validity.  Working memory and pattern separation were measured 
using the trial-unique, delayed nonmatching-to-location (TUNL) task in touchscreen-equipped 
operant conditioning chambers.  Acute MK-801 administration 25 minutes prior to task initiation 
impaired both areas of cognition.  When SNP and MK-801 were administered within 5 minutes 
of each other, no interaction was observed.  Interestingly, SNP improved performance on trials 
with difficult to discriminate patterns (p=0.058).  Previous rodent studies using the ketamine 
model of schizophrenia and the novel object preference task observed a preventative effect of 
SNP administration.  When we administered SNP nearly 4 hours prior to MK-801, no cognitive 
improvements were observed.  Our results suggest that SNP may have intrinsic cognitive 
enhancing properties but is not capable of reducing MK-801-induced working memory and 
pattern separation impairments in the TUNL task.  This study failed to mirror the results of the 
human pilot study that observed improved working memory following SNP administration.  
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Further, it did not replicate previous animal studies using ketamine.  Ultimately, the findings 
suggest that the effects of MK-801 in the TUNL task may not hold the predictive validity needed 
for its use in the study of SNP.  In order to advance the understanding of SNP, future studies 
should investigate other translatable paradigms to establish validity.             
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1.0 INTRODUCTION 
 
1.1  Schizophrenia: Cognition, Working Memory and Pattern Separation 
 
 Schizophrenia is a chronic psychiatric condition that affects nearly 1% of the population 
and is ranked among the top ten illnesses contributing to the global health burden of disease 
(Murray and Lopez 1996; McGrath et al. 2008).  This neurodevelopmental disorder is the 
consequence of an interaction between genetic susceptibility and environmental factors (Davis et 
al. 2016).  Symptom presentation, severity, and response to treatment is highly heterogeneous in 
this patient population (O’Connor and O’Shea 2015).  The symptoms of schizophrenia are 
categorized into three domains: positive, negative, and cognitive (Bozikas et al. 2004; Carbon 
and Correll 2014).  The positive symptoms are distortions in perceptual and thought-processes 
including hallucinations and delusions.  These symptoms are typically managed by conventional 
antipsychotics.  In contrast, negative symptoms include social withdrawal and anhedonia, while 
cognitive symptoms involve deficits in attention, working memory, and impulse control (Lewis 
et al. 2005).  To date, no available treatment or combination of treatments reduces symptom 
presentation across all three domains (Vingerhoets et al. 2013).  Importantly, cognitive 
symptoms are highly indicative of patient functional outcome, including community functioning 
and interpersonal interactions, implicating them in patient quality of life (Bhagyavathi et al. 
2015).  The cognitive symptoms are experienced by 80% of patients and remain stable 
throughout illness progression.  These impairments appear prior to diagnosis and may be a 
vulnerability marker of psychosis (Bora et al. 2014; Carbon and Correll 2014).  Further, 
cognitive symptoms persist after positive symptoms are managed (Nuechterlein et al. 2004; 
Young et al. 2009).  Therefore, it is imperative that treatments become available to alleviate 
these symptoms.                 
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 The Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) initiative has identified 7 cognitive domains that are typically affected in the 
disorder (Green et al. 2004).  These domain are processing speed, attention and vigilance, 
working memory, verbal learning and memory, visual learning and memory, reasoning and 
problem solving, verbal comprehension, and social cognition (Young et al. 2009).   
 Working memory is the ability to temporarily store and manipulate information.  
Impaired working memory reduces the capacity of schizophrenia patients to maintain 
information across a delay and protect it from interference (Fleming et al. 1995; Kim et al. 2004; 
Fatouros-Bergman et al. 2014).  Due to their high prevalence, robustness, and severity, working 
memory deficits have been proposed as a core component to the diagnosis (Mesholam-Gately et 
al. 2009).  Further, these impairments critically contribute to other symptoms and 
neuropsychological deficits in schizophrenia (Silver et al. 2003; Lewis and Moghaddam 2006).  
For example, disorganized speech patterns common to patients may reflect the inability to 
mentally maintain a linguistic schema (Ragland et al. 2007).  Working memory performance 
depends upon the dorsolateral prefrontal cortex (dlPFC, Ragland et al. 2007) and impairments 
may be the result of abnormal neural activation, anatomy, or integration within this region.  
Functional imaging studies have shown reduced dlPFC activation in schizophrenia patients is 
accompanied by increased activation of surrounding neural regions, however this compensation 
is insufficient to return performance to control levels (Manoach et al. 1999).  Reduced dlPFC 
activation appears specific to schizophrenia, as individuals with non-schizophrenia psychosis 
(MacDonald et al. 2005), bipolar disorder (Hamilton et al. 2009), or depression (Barch et al. 
2003) do not present with a comparable functional abnormality.  Reduced dlPFC activation 
occurs in treatment-naïve or antipsychotic-treated patients, suggesting it is not a consequence of 
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medication (Dreher et al. 2012; Kyriakopoulos et al. 2012; Koike et al. 2013).  Further, the 
subset of schizophrenia patients who do not exhibit working memory deficits present with 
increased dlPFC activation compared to controls, implying reduced dlPFC efficiency across 
patients (Callicott et al. 2003).  Patients with greater dlPFC changes perform worse on working 
memory tasks, suggesting dlPFC dysfunction correlates with symptom severity (Perlstein et al. 
2001). In addition, anatomical studies show a positive correlation between the dlPFC grey matter 
volume in schizophrenia patients and their working memory ability (Sui et al. 2015).  Other 
studies have suggested that working memory symptoms may be a consequence of functional and 
anatomical disconnections of the PFC from the rest of the brain (Zhou et al. 2015).  
 Pattern separation is the ability to keep two similar but distinct patterns as separate 
representations within the mind and evidence suggests that this cognitive function is impaired in 
schizophrenia.  Although the research exploring pattern separation impairments is limited, 
patients appear to perform worse than controls on pattern separating tasks (Das et al. 2014).  This 
impairment may be attributed to more basic visual discrimination and recognition deficits 
(Martinelli and Shergill 2015).  Pattern separation is dependent upon the dentate gyrus, a 
hippocampus region with altered functioning and reduced volume in schizophrenia (Haukvik et 
al. 2015; Faghihi and Moustafa 2015; Stan et al. 2015).  Taken together, working memory and 
pattern separation are cognitive domains impaired in schizophrenia that may reduce patient 
quality of life.   
In order to efficiently develop treatment strategies to alleviate these impairments, an 
understanding of the pathophysiological changes in schizophrenia that lead to these cognitive 
symptoms is required.  One predominant hypothesis in the literature suggests that alterations in 
the neurotransmitter glutamate and its receptors underlie the cognitive symptoms of this disease. 
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Therefore, focusing on this dysfunctional system may accelerate antipsychotic development 
(Moghaddam and Javitt 2012).    
 
1.2 Glutamate and NMDA Receptor Dysfunction in Schizophrenia 
  
 The dopamine hypothesis of schizophrenia postulates that patient symptoms result from 
dopamine dysfunction (Lieberman 2004; Lodge and Grace 2008; Javitt 2010).  Within the 
striatum and nucleus accumbens, D2 receptors are abundant and patients with schizophrenia have 
increased D2 receptor densities as well as heightened amphetamine sensitivity (Seeman 1987; 
Seeman 2006; Vinson and Conn 2012).  Increased dopamine resulting from hyperactivity of the 
mesolimbic system is thought to underlie the positive symptoms (e.g. hallucinations, delusions) 
of schizophrenia.  Lending support to this theory, typical and atypical antipsychotics antagonise 
D2 receptors and alleviate the positive symptoms (Seeman 2006; Takahashi et al. 2008).  
Similarly, increasing dopamine levels by administering a dopamine precursor, levodopa, to 
Parkinson’s patients can produce psychosis-like adverse effects including hallucinations and 
delusions (Schumacher-Schuh et al. 2013).  However, the negative and cognitive symptoms of 
schizophrenia are unresponsive to D2 receptor antagonists (Vinson and Conn 2012).  The 
dopamine hypothesis was later extended to include dysfunction of the mesocortical pathway as 
the mechanism underlying the negative and cognitive symptoms (Laruelle 2014).  Specifically, 
reduced D1 receptor binding within the PFC is implicated in the working memory impairments of 
schizophrenia (Lieberman 2004).  It has also been proposed that dopaminergic changes in 
patients may be secondary to glutamate dysfunction.      
 Glutamate is the primary excitatory neurotransmitter within the central nervous system 
and is found within 40% of all human synapses (Tsai and Coyle 2002).  Glutamate receptors are 
classed as either metabotropic or ionotropic (Ozawa et al. 1998).  Metabotropic glutamate 
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(mGlu) receptors are G-protein coupled and utilize secondary messenger cascades.  These 
receptors modulate glutamate release and receptor function (Schoepp and Conn 1993).  The 
second class of glutamate receptors are ionotropic.  These receptors are ligand-gated ion 
channels, permeable to cations, and responsible for fast, excitatory post-synaptic potentials.  
There are three identified ionotropic receptors:  alpha-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA), N-methyl-D-aspartate (NMDA), and kainate receptors (Lewis and 
Moghaddam 2006).  All three types of ionotropic receptors have been implicated in 
schizophrenia (Kerwin et al. 1990; Breese et al. 1995) and are believed to contribute to the 
disease but the majority of evidence emphasizes the critical role of NMDA receptors in 
schizophrenia.      
 NMDA receptor activation requires ligand-binding and a voltage change in the neuronal 
membrane.  More specifically, their activation requires glutamate and glycine co-binding to their 
respective sites.  In addition, a partial membrane depolarization is required to remove 
noncompetitively bound magnesium ions within the receptor pore (Dingledine et al. 1999).  
NMDA receptors are located at excitatory synapses throughout the brain, with particularly high 
densities in cortical and subcortical regions (Monaghan and Cotman 1985; Monaghan et al. 
1988).  Activation of these receptors is required for long-term potentiation, a mechanism of 
synaptic plasticity, and blocking NMDA receptor function impairs learning and memory 
(Robbins and Murphy 2006). Several lines of evidence support the role of NMDA hypofunction 
in schizophrenia.  Initial support followed the observation that behaviors similar to schizophrenia 
were produced following treatment with an NMDA receptor antagonist, such as ketamine, 
phencyclidine (PCP), or Dizocilpine (MK-801).  The experiences of non-schizophrenic subjects 
administered ketamine replicated the positive, negative and cognitive symptom domains of 
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schizophrenia to a level indistinguishable from patients (Krystal et al. 1994; Adler et al. 1999).  
Further, when ketamine was administered to schizophrenia patients, symptoms were exacerbated 
(Malhotra, 1997).  Patients with schizophrenia have a reduced level of NMDA receptor subunits 
in the PFC, including the dlPFC (Errico et al. 2013; Dean et al. 2016).  Further, levels of 
endogenous NMDA receptor agonists are also reduced in patients with schizophrenia and non-
medicated patients exhibit reduced NMDA receptor binding compared to healthy controls 
(Pilowsky et al. 2006; Errico et al. 2013).  
 NMDA receptors are implicated in the clinical manifestation of schizophrenia leading to 
alterations in glutamatergic as well as other neurotransmitter systems.  Within the 
thalamocortical circuit, glutamate binds to NMDA receptors on inhibitory interneurons within 
the mediodorsal thalamus.  These GABAergic interneurons synapse onto glutamatergic thalamic 
neurons, which project to pyramidal cells with PFC.  When NMDA receptor function is reduced, 
depolarization of interneurons is impeded, resulting in impaired GABAergic inhibition.  This 
disinhibition increases the glutamatergic excitatory firing in the PFC (Moghaddam et al. 1997; 
Vinson and Conn 2012).   NMDA receptor dysfunction may also have secondary effects on the 
dopamine system.  Chronic administration of NMDA receptor antagonists increasing dopamine 
levels in subcortical regions (Laruelle 2014).  Further, NMDA receptor antagonist treatment 
increases glutamate function in the ventral tegmental area, stimulating mesolimbic dopamine 
transmission (Mathé et al. 1998; Jentsch et al. 1998).  Therefore, reducing NMDA receptor 
function in rodents may enable the pathophysiological changes in schizophrenia to be greater 
understood. 
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1.3 NMDA Receptor Hypofunction as a Model of Schizophrenia 
 Animal models of disease bypass the ethical restraints that restrict clinical 
experimentation and provide a better understanding of human conditions (Markou et al. 2009).  
One way to induce a disease-like state in rodents is using pharmacological manipulations.  By 
administering specific receptor agonists or antagonists, animal models can be produced that 
mimic precise pathophysiological changes within a disease.  A key advantage of 
pharmacological models is that they provide a researcher with temporal and spatial control 
(Nestler and Hyman 2010).  As mentioned, patients with schizophrenia have reduced functioning 
of NMDA receptors and administration of non-competitive NMDA receptor antagonists in 
controls induces a schizophrenia-like phenotype (Krystal et al. 1994; Adler et al. 1999; Errico et 
al. 2013).  Similarly, non-competitive NMDA receptor antagonism in rodents produces behaviors 
analogous to the positive, negative, and cognitive symptoms of schizophrenia (Moghaddam and 
Krystal 2012).  For example, locomotor hyperactivity (Manahan-Vaughan et al. 2008; Howland 
et al. 2012; Zemanova et al. 2013; Mahmood et al. 2016), reduced sociability (Morales and Spear 
2014), and performance deficits on visual learning and working memory tasks (Brown et al. 
2013; Zemanova et al. 2013; Kumar et al. 2015b; Kumar et al. 2015a; Lins and Howland 2016) 
are observed following MK-801 administration, mirroring the positive, negative, and cognitive 
symptoms respectively.  Beyond its direct effect on NMDA receptors, MK-801 administration 
indirectly mimics other pathophysiological features of the disease (Lewis et al. 2005).   
 Noncompetitive NMDA receptor antagonists preferentially bind to NMDA receptors 
located on γ-Aminobutyric acid (GABA)-releasing interneurons (Coyle 2012).  At sub-anesthetic 
doses, ketamine increased extracellular glutamate in the PFC (Coyle 2012).  This is because the 
effect of NMDA receptor antagonists on GABAergic interneurons impairs the inhibition of these 
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neurons on thalamic glutamatergic neurons.  Glutamatergic neurons then project to PFC 
pyramidal neurons and increase the excitatory firing in the PFC (Moghaddam et al. 1997; Vinson 
and Conn 2012). More specifically, sub-anesthetic doses of MK-801 bind to interneurons 
containing parvalbumin (PV), a calcium-binding protein.  Interneurons containing parvalbumin 
(PV+) are fast spiking and produce non-adaptive firing patterns.  PV+ cells innervate pyramidal 
neurons, at their soma (basket cells) or their axon (chandelier cells), and other interneurons that 
target proximal dendrites of projection neurons (Lewis et al. 2005).  These PV+ interneurons 
may be particularly vulnerable to glutamate dysfunction for several reasons (Lewis and 
Moghaddam 2006).  First, these cells receive more excitatory inputs from pyramidal neurons 
than other GABA subtypes in the prefrontal cortex (PFC) and hippocampus (Gulyás et al. 1999; 
Melchitzky and Lewis 2003).  Second, these PV+ interneurons express more glutamate receptor 
subunits within the temporal cortex and PFC.  For example, the R1 subunit of NMDA receptors 
is expressed in more PV+ than other interneurons (Huntley et al. 1997; González-Albo et al. 
2001).  Lastly, the activation of PV+ interneurons may be highly dependent upon glutamate 
receptor activation, resulting in their high sensitivity and vulnerability to NMDA receptor 
antagonism (Lewis and Moghaddam 2006).  NMDA receptor antagonism reduces PV mRNA 
expression levels by up to 25% in the PFC in rodents without changing neuron density, 
suggesting these neurons have the capacity to alter PV+ interneuron translational processes 
(Cochran et al. 2003).  The preferential binding of non-competitive NMDA receptor antagonists 
to GABAergic, specifically PV+ interneurons, indirectly models altered GABA function in 
schizophrenia and may be related to working memory symptoms.  
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1.4 Validity of the Acute MK-801 Model 
 Animal models are critical to the advancement of novel therapeutic drug production but 
no animal model perfectly replicates human disorders (Markou et al. 2009).  In the case of 
schizophrenia, modeling the disease is particularly tricky.  The diagnosis of schizophrenia, 
similar to other psychiatric disorders, is based on clinical observations and occurs without 
objective physiological irregularities such as changes in synapses, cells, or neural circuits.  
Further, schizophrenia is marked by aspects of the disease that appear to be uniquely human, 
such as psychosis.  Even in the case of more concrete disease characteristics, including cognitive 
impairments, animal behavioral changes are only approximated to human resemblance. 
Accounting for these short-comings, animal models of schizophrenia provide irreplaceable 
insight into the condition (Nestler and Hyman 2010).  Therefore, the strengths and limitations of 
an applied model must be appreciated in order to draw appropriate conclusions from data 
(Markou et al. 2009).    
 Three types of validity have been proposed to the assess an animal models clinical utility: 
etiological, face, and predictive (Nestler and Hyman 2010).  The acute MK-801 model of 
schizophrenia can be evaluated for each type.  Etiological validity measures how consistent the 
development of the modeled condition is with the human disorder.  The development of 
schizophrenia is due to an interplay between genetic and environmental factors (Davis et al. 
2016).  Therefore, the acute administration and short-term behavioral changes that follow a 
single MK-801 injection are indicative of limited etiological validity.  In contrast to 
pharmacological models, models rooted in genetic or environmental manipulations produce 
chronic behavioral changes and more closely replicate cause of the schizophrenia.  However, 
high etiological validity can come at a cost.  When measuring cognition, testing may be 
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confounded by differences in learning (Vorhees et al. 2012; Vorhees et al. 2015).  In addition, 
these models often produce a variety of nonspecific and diverse neurological changes, thus 
preventing the study of isolated systems (Hadar et al. 2015). The second type of validity used in 
the assessment of animal models is face validity.  Face validity is the degree to which a model 
presents with the pathophysiological manifestations and behavioral changes seen in a disease 
state (Nestler and Hyman 2010).  An acute injection of MK-801 produces neural and behavioral 
changes similar to those seen in schizophrenia (see 1.2 MK-801 Model of Schizophrenia).  As 
mentioned, schizophrenia is characterized by NMDA receptor dysfunction, reduced PV+ 
interneuron GABA transmission, and three symptom domains.  The acute MK-801 model of 
schizophrenia demonstrates high face validity because rodents administered the drug display 
similar changes (Lewis et al. 2005; Moghaddam and Krystal 2012).  Predictive validity is the 
final measure of clinical utility and is directly related to the development of novel drugs.  
Sometimes termed pharmacological validity, predictive validity is the capacity of a model to 
foreshadow how a patient population will respond to a treatment.  In experiments assessing 
predictive validity, negative controls are drugs known to be ineffective in patients.  At best, 
haloperidol, clozapine, and other conventional antipsychotics inconsistently and moderately 
reduce the cognitive symptoms of schizophrenia (Feinstein and Kritzer 2013).  In contrast, a 
positive control is the “gold standard” drug used in comparison with the new treatment.  This 
drug is believed to be of the highest available quality and tends to be the most frequently 
prescribed for the condition.  Unfortunately, no available drugs alleviate the cognitive symptoms 
of schizophrenia and the lack of a positive control prevents the thorough evaluation of an animal 
model’s predictive validity (Markou et al. 2009).  Predictive validity of the acute MK-801 model 
of schizophrenia is inconsistent (Adell et al. 2012).  However, this may be a consequence of the 
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task translatability in assessing novel treatments in the MK-801 model, rather than the model 
itself.  
 
1.5 Trial-Unique, Delayed Nonmatching-to-Location Task 
 
 Within the last decade, several reports have highlighted the suboptimal progress in novel 
pharmaceutical development, particularly emphasising the halt in psychiatric disorders (Markou 
et al. 2009; Nestler and Hyman 2010).  In the case of schizophrenia, the tasks used to measure 
cognitive function in animals may be a key hindrance (Nestler and Hyman 2010).  By developing 
assessments with high cross-species applicability, failed clinical drug trials will be reduced and 
the understanding and treating of human conditions using novel drugs will become more rapid 
(Markou et al. 2009).  
 One rodent task used to assess working memory is the delayed nonmatching-to-position 
paradigm.  During this task, a rat is presented with a lever in one of two positions.  After pushing 
the lever and a subsequent delay, two levers are presented in each location.  To be rewarded, the 
non-matched lever must be pressed (Sloan et al. 2006).  The usefulness of this task was 
questioned following the observation that trained rats developed mediating strategies to improve 
performance, thereby reducing reliance on memory (Chudasama and Muir 1997; Panlilio et al. 
2011).  The Trial-Unique, Delayed Nonmatching-to-Location (TUNL) task was developed to 
address the weaknesses of the delayed nonmatching-to-position task.  The TUNL task is 
conducted in touchscreen-equipped operant conditioning chambers (Oomen et al. 2013).  By 
using an automated touchscreen system, variability amongst trials is reduced and researcher bias 
during data collection is eliminated (Talpos et al. 2010; Oomen et al. 2013).  Further, this system 
makes the administration of tasks simple, time-efficient, and consistent.  The touchscreen is 
covered with a mask composed of 14 open squares and each trial is composed of three phases 
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(Figure 1).  During the sample phase, 1 of the 14 squares becomes lit and a rat nose-pokes the 
square.  This is followed immediately by a delay phase lasting for a predetermined period of 
time.  After the delay, the rat pokes its nose into a port at the opposite end of the operant 
chamber to queue the choice phase.  During the choice phase, the previously-lit sample square 
and a novel square become lit and the rat must correctly non-match by selecting the novel square 
to obtain a food reward.  The location of the correct square is random and cannot be predicted by 
the rat, reducing the likelihood of mediating strategies (Talpos et al. 2010).  By manipulating the 
length of delay and distance between the sample and choice square, the demand on working 
memory and pattern separation can be respectively altered.  For example, longer delays require a 
greater demand on working memory and closer together squares are more difficult to maintain as 
separate patterns (Oomen et al. 2013).  As mentioned, one way to improve the predictive validity 
is to focus on the preclinical-clinical translation of cognitive tasks.  Reduced disparity between 
preclinical and clinical measures is likely to enhance predictive validity in animal models of 
disease.  Similar to animal models, it is important to critically evaluate the validity of a task to 
ensure it is appropriate for the cognitive domain being studied.  Construct validity indicates 
whether the domain measured by an animal task is similar to the human cognitive domain it is 
being compared to (Markou et al. 2009).  One way to measure this is by comparing the neural 
correlates underlying the domain in both species. 
 In humans, working memory is dependent upon the dlPFC and functional alterations in 
this region are observed in patients with schizophrenia (Lewis and Moghaddam 2006).  
Therefore, if TUNL were to show construct validity for working memory then lesions to the 
medial PFC (mPFC), the rodent cortical region equivalent to the human dlPFC, should impair 
performance.  Indeed, when the mPFC is lesioned, rats perform significantly worse than shams 
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following longer delays, regardless of the pattern separation difficulty.  Further supporting the 
mPFC in the working memory component of the TUNL task, the removal of inter-trial intervals 
produces performance interference following PFC lesions (McAllister et al. 2013).  Pattern 
separation is heavily reliant on the dentate gyrus in humans (Gaffan 1985).  Rodents are sensitive 
to the effects of pattern separation on the TUNL task, as smaller separations between sample and 
choice stimuli reduces accuracy.  However, this reduction is exaggerated in rats with 
hippocampal lesions.  This reflects the hippocampal dependence in pattern separation (Talpos et 
al. 2010).  Taken together, these two findings suggest that the TUNL task has high construct 
validity and may be appropriate to measure working memory in rodent models of schizophrenia.      
       
1.6 Alleviation of the Cognitive symptoms 
 Current antipsychotics alleviate the positive symptoms of schizophrenia, including 
hallucinations and delusions, that are core to the DSM diagnostic criteria and a hallmark of the 
disease.  However, negative and cognitive symptoms are severe and associated with long-term 
disability yet are untreated by conventional antipsychotics (Hyman and Fenton 2003).     
 The hypothesis that NMDA receptor hypofunction underlies the cognitive symptoms of 
schizophrenia has created a new model and target in novel pharmaceutical development focused 
on improving this disruption (Matsui et al. 1995).  NMDA receptor activation requires the co-
binding of glutamate and glycine (Dingledine et al. 1999),  thus administering agonists to these 
binding sites may recover NMDA receptor function.  Exogenous glutamate leads to nervous 
system damage, therefore research primarily focused on targeting the glycine site (Olney 1990; 
Tsai et al. 1999; Tsai and Coyle 2002; Tsai et al. 2006).  Although co-administration of glycine 
with ongoing antipsychotic treatment reduced symptoms in patients even after its 
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discontinuation, these improvements were inconsistent (Evins et al. 2000; Javitt et al. 2001; 
Heresco-Levy et al. 2004; Buchanan et al. 2007).  A meta-analysis of 18 short-term trials found 
that D-serine or glycine, NMDA receptor agonists to the glycine site, reduced the negative 
symptoms of schizophrenia but the results were inconsistent and the findings were inconclusive.  
In addition, D-cycloserine, a partial agonist of the NMDA receptor glycine site, was ineffective 
at reducing any patient symptoms (Tuominen et al. 2006).  Pharmacological shortcomings in 
clinical trials are not limited to glutamatergic targets.  Putative antipsychotics that alter 
dopaminergic, serotoninergic and cholinergic mechanisms have also reached clinical trials but 
have not produced desired results (Carbon and Correll 2014).   
 Most commonly, drug discovery is unidirectional, with information flowing from 
preclinical to clinical studies (Markou et al. 2009).  It often begins with the identification of a 
particular target.  In vitro studies give insight into the practical aspects of novel pharmaceutical 
development such as cellular toxicity, metabolism as well as other pharmacodynamics and 
pharmacokinetic properties.  However, clinical efficacy is initially studied using in vivo animal 
models and eventually progresses into human clinical trials (Markou et al. 2009).  Unfortunately, 
this prevents the pragmatic and rational modification of animal experiments. Sodium 
nitroprusside (SNP) is a nitric oxide donor with a developed clinical profile that is traditionally 
used to treat hypertensive crisis in clinical settings (World Health Organization 2014). Recently, 
SNP has shown promise as an adjunct treatment to alleviate the cognitive symptoms of 
schizophrenia, presenting a unique situation whereby human and rodent study can happen 
simultaneously (Maia-de-Oliveira et al. 2015a).  SNP is a water soluble salt with the chemical 
formula Na2[Fe(CN)5NO].  In hypertensive crisis (World Health Organization 2015), SNP 
reduces mean arterial blood pressure and vascular resistance, while increasing cardiac output.  
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This potent molecule induces rapid venous and arterial vasodilation.  The onset of vascular 
effects is virtually immediate and begins within 30 s of administration.  Once infusion is 
completed, the effects rapidly dissipate and the half-life of SNP is < 2 minutes.  Patients with 
schizophrenia were administered SNP adjunct to their antipsychotic treatment and, eight hours 
following SNP administration, patients had improved performance on the Stroop and n-back 
task.  This is indicative of reduced selective attention and working memory impairments 
respectively (Maia-de-Oliveira et al. 2015a).  Further, positive and negative symptoms were 
reduced following a single treatment for up to four weeks (Hallak et al. 2013).  Taken together, 
these studies suggest that SNP in conjunction with antipsychotics may lead to reduced symptom 
presentation in all three symptom domains long-term.  
 
1.7 Rationale and Hypotheses 
 Nitric oxide function is altered in schizophrenia, implicating it as a potential mechanism 
for pharmaceutical treatment (Beninger et al. 2009).  Recently, human clinical trials have reduce 
positive, negative and some cognitive symptoms in schizophrenia following the administration of 
SNP (Hallak et al. 2013; Maia-de-Oliveira et al. 2015a).  Importantly, one of the assessed 
cognitive domains was working memory (Maia-de-Oliveira et al. 2015a).  Although the precise 
mechanisms underlying this effect are unknown, SNP has revealed promise in the treatment of 
all three symptom domains of schizophrenia. 
 The overarching aim of this thesis is to determine whether MK-801-induced impairments 
in the TUNL task are an appropriate model of cognitive impairment in schizophrenia to study the 
effects of SNP.  Although this model has demonstrated face validity in other tasks, its predictive 
validity is inconsistent.  Thus, the first objective of this research is to demonstrate the face 
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validity of the MK-801 model of schizophrenia in the TUNL task.  Only one previous study has 
investigated performance changes following acute MK-801 administration in the TUNL task 
(Kumar et al. 2015a).  The results of this experiment showed 0.05 mg/kg of MK-801 impaired 
task accuracy with 1 s and 20 s delays.  In the current experiments, we will expand on the 
previous findings by using less dramatic differences in delay.  It is hypothesized that acute MK-
801 administration will disrupt TUNL task performance and reduce accuracy on trials with 2 s 
and 6 s delays and face validity of MK-801 in the TUNL task will be demonstrated.  Further, 
previous studies have identified perseverative errors following MK-801 administration (Lins et 
al. 2015), and we expect MK-801 will increase the number of correction trials completed by a rat 
during the TUNL task.     
The second objective is to explore the therapeutic potential of SNP using the MK-801 
model in the TUNL task.  Human studies have suggested SNP as an adjunct treatment to reduce 
working memory impairments in schizophrenia patients (Maia-de-Oliveira et al. 2015a).  
Further, SNP has the potential to prevent and rescue ketamine-induced impairments in cognitive 
tasks (Kandratavicius et al. 2015; Maia-de-Oliveira et al. 2015b).  Therefore, it is hypothesized 
that, similar to ketamine studies, acute MK-801-induced impairments on the TUNL task will be 
reversed when rats are pre- or co- treated with SNP.  If SNP reduces MK-801-induced 
impairments, then the MK-801 model in the TUNL task will demonstrate predictive validity and 
the paradigm may be used in future animal studies for SNP in schizophrenia.      
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2.2 Abstract 
 
Rationale: The cognitive symptoms observed in schizophrenia are not alleviated by conventional 
antipsychotics.  Following a recent pilot study, Sodium Nitroprusside (SNP) has been identified 
as a promising adjunct treatment to reduce the working memory impairments experienced by 
schizophrenia patients. 
Objective: The present experiments aimed to explore the effects of SNP on the acute MK-801 
rodent model of schizophrenia using the highly translatable trial-unique, delayed nonmatching-
to-location (TUNL) task to examine the face and predictive validity of this model.     
Methods: SNP (0.5, 1.0, 2.0, 4.0 mg/kg) and MK-801 (0.05, 0.075, 0.1 mg/kg) were acutely 
administered to rats trained on the TUNL task. 
Results: Acute MK-801 treatment impaired TUNL task accuracy.  Administration of SNP (2.0 
mg/kg) with MK-801 (0.1 mg/kg) failed to rescue performance on TUNL.  SNP (5.0 mg/kg) 
administration nearly 4 hours prior to MK-801 (0.05 mg/kg) treatment had no preventative effect 
on performance impairments.  SNP (2.0 mg/kg) improved performance on a subset of trials.     
Conclusion:  These results suggest that SNP may possess intrinsic cognitive-enhancing 
properties but is unable to block the effects of MK-801 treatment on the TUNL task.  This 
experiment does not mirror the alleviating effects of SNP in schizophrenia patients, suggesting 
that MK-801 in the TUNL task may not hold the predictive validity necessary for its use in the 
study of SNP as a treatment in schizophrenia.   
 
Key words: schizophrenia, NMDA receptor, nitric oxide donor, working memory, pattern 
separation 
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2.3 Introduction 
 Schizophrenia affects 0.7% of the population (McGrath et al. 2008) and is characterized 
by positive, negative, and cognitive symptoms (Carbon and Correll 2014).  The cognitive 
symptoms are distinct and core characteristics associated with the disease (Bozikas et al. 2004; 
Aquila and Citrome 2015) and their severity influences patient functional outcome (Bhagyavathi 
et al. 2015).  Although these symptoms are experienced by the majority of patients, they remain 
unresolved by available antipsychotic treatments (Palmer et al. 1997).  Working memory deficits 
have been emphasized as key impairments in schizophrenia by the Measurement and Treatment 
Research to Improve Cognition in Schizophrenia (MATRICS) initiative (Marder and Fenton 
2004).  Working memory impairments are robust and highly prevalent among patients 
(Mesholam-Gately et al. 2009).  The severity of impairment is highlighted by the collection of 
working memory vulnerabilities, including the inability to maintain information across a delay or 
protect it from interference (Fleming et al. 1995; Kim et al. 2004; Fatouros-Bergman et al. 2014).  
Pattern separation, the ability to keep separate patterns as distinct internal representations, is a 
less frequently studied domain of cognition impaired in schizophrenia.  This impairment is 
observed in reduced accuracy on tasks that require face matching, matching-to-sample, or the 
spatial discrimination of sound (Perrin et al. 2010; Soria Bauser et al. 2012).  The trial-unique, 
delayed nonmatching-to-location (TUNL) task simultaneously measures working memory and 
pattern separation in rodents.  The high cross-species translatability of this task makes it a 
promising and unique platform to study potential treatment of cognitive impairment in 
schizophrenia (Bussey et al. 2012).  To date, only one experiment has examined task 
performance in a rodent model of schizophrenia (Kumar et al. 2015a) and none have attempted 
to reverse any observed impairments.      
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Sodium Nitroprusside (SNP) is a nitric oxide donor that is traditionally used to treat 
hypertensive crisis by rapidly inducing arterial and venous vasodilation (Hottinger et al. 2014).  
Recently, SNP has been investigated as an adjunct treatment to reduce symptom severity in 
schizophrenia.  Intravenous administration of SNP significantly reduced the positive, negative 
and cognitive symptoms experienced by schizophrenia patients (Hallak et al. 2013; Maia-de-
Oliveira et al. 2015a).  Of particular importance, patient performance improved 8 hours after 
SNP administration on working memory and selective attention tasks (Maia-de-Oliveira et al. 
2015a).  Although cognitive changes were not examined in a subsequent follow-up, positive and 
negative symptoms were reduced four weeks following the single SNP infusion (Hallak et al. 
2013).  This suggests that SNP may alleviate all three symptom domains of schizophrenia over 
long-term periods.  Rodent studies using acute NMDA receptor antagonist models of 
schizophrenia have mirrored the human findings.  In these studies, the administration of SNP in 
conjunction with an NMDA receptor antagonist attenuated locomotor behavior, social behavior, 
and novel object recognition abnormalities.  These measurements are believed to be rodent 
analogues to aspects of the positive, negative and cognitive symptoms of schizophrenia (Maia-
de-Oliveira et al. 2015b; Trevlopoulou et al. 2016).  Rodent effects were observed up to one 
week after administration, further supporting the long-term efficacy of SNP (Maia-de-Oliveira et 
al. 2015b).  Although the mechanism underlying these changes are not fully understood, this 
evidence supports SNP as a viable treatment to alleviate the symptoms of schizophrenia and 
improve patient quality of life.  SNP is different from putative antipsychotics, whose 
unidirectional study begins in animal models and proceeds to humans, because its medical 
application (Friederich and Butterworth 1995) allows SNP to be concurrently studied in clinical 
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populations and animal models.  The present study aims to exploit the bidirectional study of SNP 
to explore the predictive validity of an animal model of schizophrenia.   
NMDA receptor dysfunction is a pathophysiological change implicated in the symptom 
manifestation of schizophrenia.  Human controls who received a non-competitive NMDA 
receptor antagonist, such as ketamine or phencyclidine, present with a schizophrenia-like 
phenotype that is indistinguishable from symptoms exhibited by schizophrenia patients (Krystal 
et al. 1994; Adler et al. 1999).  Further, these drugs exacerbate symptoms in diagnosed patients 
(Malhotra 1997).  Non-competitive NMDA receptor antagonism in rats has demonstrated face 
validity as model of schizophrenia (Moghaddam and Krystal 2012).  Specifically, impaired 
working memory performance has been observed as MK-801 administration in rodents reduces 
performance on the TUNL task (Kumar et al. 2015a).  However, the predictive validity of this 
model is difficult to interpret as there are currently no positive controls that reduce cognitive 
symptom presentation in schizophrenia patients (Markou et al. 2009).  Therefore, the primary 
aim of the proposed experiment is to explore the effects of SNP on MK-801-induced working 
memory impairments in the TUNL task in order further characterize its pharmacological validity 
as a rodent model of schizophrenia.  As mentioned, the TUNL task possesses high translational 
capacity, making it an ideal platform to study predictive validity (Bussey et al. 2012).  The 
secondary aim of this research is to explore the effects of SNP on pattern separation following 
MK-801 administration.     
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2.4 Materials and Methods 
2.4.1 Subjects 
 Forty-four male Long-Evans rats were trained on the TUNL task in two separate cohorts, 
referred to as Squad 1 (n=22; Charles River Laboratories, Quebec, Canada) and Squad 2 (n=20; 
Charles River Laboratories, New York, USA).  All subjects were housed in clear, ventilated 
plastic cages and contained within a temperature-controlled vivarium.  Animals were given in-
cage enrichment consisting of a plastic tube.  Rats were maintained on a 12h:12h light-dark cycle 
and all experimental procedures were completed during the light phase.  Subjects were food 
restricted in order to maintain 85% of their free-feeding weight with normal growth accounted 
for.  Water was available ad libitum, except during testing.  All experiments were approved by 
the University of Saskatchewan Research Ethics Board and were conducted in accordance with 
the standards of the Canadian Council on Animal Care.     
2.4.2 Training Apparatus 
 All experimental training and testing occurred within eight touchscreen-equipped operant 
conditioning chambers (Lafayette Instruments, Lafayette, IN, USA).  Each individual chamber 
was trapezoidal in shape, with the face of the wide edge comprised of a touchscreen (Fig 1.).  
The touchscreen was covered by a black polycarbonate mask with 14 small squares arranged in a 
7x2 pattern.  The lower part of the mask was covered by a spring-loaded “response shelf” that 
rats must intentionally use in order to touch the exposed touchscreen.  On the opposite end of the 
chamber was a food magazine where odorless reward pellets (Dustless Precision Pellets, 45 mg, 
Rodent Purified Diet; BioServ, Frenchtown, NJ) were dispensed.  This food magazine also 
contained a reward light and an infra-red nose-poke detector.  The floor of the chamber was  
	   	   	  
23	  
  
Fig 1 Touchscreen-equipped operant chamber and task schematic. A. Flow chart depicting 
TUNL trial procedure and outcome.  See Methods for procedural details.  B. Photograph of the 
touchscreen apparatus and stimuli presentation corresponding to the choice phase of the task.  C. 
Samples of the two categories of pattern separations (large and small).  
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composed of metal mesh and the roof was a plastic lid.  Each operant conditioning chamber was 
located on a sliding shelf at the base of a sound-attenuating large wooden box.  In  
addition to the operant conditioning chamber, boxes contained a pellet dispenser, video camera, 
small ventilation fan, and a house light that was activated following incorrect responses.  
2.4.3 Handling and Habituation 
 Rats were undisturbed in the vivarium for a minimum of five days following their arrival 
and then individually handled for three consecutive days.  Throughout handling, rats were placed 
on carts and travelled from the vivarium, up an elevator, to the touchscreen room in order to 
familiarize them with the route of transportation.  Following handling, rats were habituated.  On 
the first day of habituation, rats were left in the touchscreen room for one hour with all 
technology turned on (2 computers and 8 chambers).  Ten reward pellets were placed in each 
home cage to familiarize them with the food reward.  Rats were left undisturbed in the 
touchscreen room for 15 minutes prior to being placed in the operant conditioning chambers on 
all proceeding training and testing days.  Due to the limited number of chambers, rats were run in 
groups of 8 and an effort was made to consistently put rats into the same chamber throughout 
training and testing.  During the second and third days of habituation, rats were placed into the 
operant conditioning chambers for 30 minutes with 10 pellets in the food reward port.  The 
chambers were turned on but no stimuli was present on the screen.  All behavior was recorded 
within the touchscreens and an external monitor presented a live video feed of each rat’s activity. 
2.4.4 TUNL Pretraining 
 The pretraining protocol followed a modified version of the instructions and software 
provided by Lafayette that accompanied the touchscreen chambers and each phase was repeated 
until criterion was reached.  TUNL pretraining was composed of four training stages: initial 
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touch, must touch, must initiate, and punish incorrect.  Initial Touch Training introduced the 
relationship between touchscreen stimuli and a food reward.  During each trial, 1 of 14 squares 
was illuminated.  If a rat touched the illuminated square, 3 reward pellets were immediately 
dispensed but if the square was not touched after 30 seconds, the stimulus was removed and a 
single reward pellet was dispensed.  Each trial was proceeded by a 20s inter-trial interval (ITI).  
Rats must have completed 100 trials in 60 minutes to reach criterion. The Must Touch Training 
was similar to Initial Touch Training but the square remained illuminated until it was touched by 
a rat.  Touching the square led to a single reward pellet being dispensed and criterion was 100 
trials in 60 minutes.  The proceeding Must Initiate Training required a rat to poke its nose in the 
food magazine to initiate trials identical to those in Must Touch Training.  Criterion was 100 
trials in 1 hour.  The final pretraining stage was Punish Incorrect Training; each trial began with 
a rat poking its nose into the food reward port, leading to the presentation of a stimulus.  If a rat 
touched the stimulus, a reward pellet was dispensed and a new trial initiated following an ITI.  
However, if the rat touched an unilluminated square, a timeout began.  During a timeout, no 
reward pellet was dispensed and the house light turned on for 5 s followed by an ITI.  The 
previous trial was then repeated until the rat correctly selected the stimulus; these repeated trials 
were termed as ‘correction trials’.  Criterion was the completion of 100 trials within 60 minutes 
with >80% accuracy on two consecutive days.   
2.4.5 TUNL Task Acquisition 
 Once a rat completed pretraining, it immediately began learning the standard TUNL task 
(Fig. 1).  Each trial began by a rat poking its nose into the reward magazine and initiating the 
sample phase where 1 of 14 squares was lit.  Once the lit square was touched, the stimulus was 
removed from the screen and a 2 s delay began.  In 33% of trials a reward pellet was dispensed 
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in order to maintain motivation.  Following the delay, the rat was required to poke its nose into 
the reward magazine to start the choice phase.  During this phase, the sample square and a novel 
square were illuminated simultaneously.  A correct response was made when a rat non-matched 
to the sample square and touched the novel square.  Correct responses were rewarded with 
reward pellet and followed by a 20s ITI.  A new ‘selection trial’ began at the end of the ITI, with 
different stimuli from the previous trial.  If an incorrect response was made, with the rat selecting 
the sample square, the house light turned on for 5 s and no reward was dispensed.  This time out 
was followed by a 20 s ITI and the proceeding trial was identical to the previous one.  Trials that 
repeat the most recent selection trial are termed ‘correction trials’ and are repeated consecutively 
until the correct response is made.  Accuracy was a measure of the percent of correct responses 
made during selection trials.  Rats were initially trained to complete 40 trials with >75% in 35 
minutes.  Following this, the second criterion required was 70 trials with >75% correct in 1 h.  
Rats treated with SNP and MK-801 received additional training that included 2 and 6 s delays 
with criterion set at 75% accuracy on a session over 2 consecutive days.  Once the last criterion 
was met, rats were left undisturbed in the vivarium while the remaining rats were trained to 
criterion.  Rats were given reminder training sessions once a week to maintain performance until 
testing began (Oomen et al. 2013).  Once all rats were trained to the second criterion, they were 
reintroduced to daily testing for at least three days to collect baseline measurements prior to drug 
treatment.  Animals that failed to reach criterion were not used for subsequent testing.  
2.4.6 Drug Treatments  
 The order of treatment administration was counterbalanced using a within-subjects 
design.  Rats receiving MK-801 and SNP was quasi-randomly assigned such that MK-801 was 
not administered on two consecutive treatment days.  Dose received for dose-response curve data 
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was given in ascending order with the initial treatment counterbalanced across rats.  MK-801 
(Abcam, Cambridge, MA) and SNP (Sigma-Aldrich, St. Louis, MO) were dissolved in saline and 
drugs were protected from light exposure to prevent photodecomposition (Bisset et al. 1981).  
All injection volumes were 1.0 mL/kg body weight and saline was used as the vehicle treatment.  
The doses of MK-801 and SNP used in the TUNL task were determined from existing literature 
and previously published touchscreen data collected within our lab (Gourgiotis et al. 2012; 
Kandratavicius et al. 2015; Maia-de-Oliveira et al. 2015b; Kumar et al. 2015a; Lins et al. 2015; 
Lins and Howland 2016). Dose-response curve data were collected following intraperitoneal 
administration of MK-801, SNP, or saline 25 minutes prior to starting the TUNL task.  
Treatment-free days were allowed between testing and baseline measurements were recollected 
prior to each treatment to ensure a sufficient washout period.  A total of 5 rats (1 from squad 1 
and 4 from squad 2) did not learn the task and were not treated.  Rats trained in squad 1 were 
used for the MK-801 dose-response curve (n=10; 0.05, 0.075, 0.1 mg/kg), SNP dose-response 
curve (n=10; 0.5, 1.0, 2.0, and 4.0 mg/kg) and the reversal experiment (rats treated with SNP (2.0 
mg/kg) 5 minutes prior to MK-801 administration (0.1 mg/kg), n=12).  Due to the extensive 
training required to learn the task, squad 1 animals (n=22) were reused in drug testing:  SNP 
dose-response curve only (n=7), reversal only (n=5), SNP and MK-801 dose-response curves 
(n=3), MK-801 dose-response curve and reversal (n=7).  In squad 2, the preventative effect of 
SNP was explored.  SNP (5.0 mg/kg, i.p.) was administered 3 h and 35 minutes prior to MK-801 
(0.05 mg/kg, i.p.) and 4 h prior to the beginning of TUNL task.   
2.4.7 Statistical Analysis 
 The fully automated nature of the touchscreen procedure and data collection eliminates 
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error of the mean (SEM).  The dependent measures analyzed include overall accuracy (% correct 
on selection trials), accuracy on 2 s delay trials, accuracy on 6 s delay trials, accuracy on large 
separation trials (Fig 1C; minimum of 4 squares between sample and choice stimuli), accuracy 
on small separation trials (Fig 1C; 1-2 squares between sample and choice stimuli), number of 
selection trials completed (number of different stimuli presentations), number of correction trials 
completed (trials replicating selection trials), total trials completed (selection trials plus 
correction trials), mean reward collection latency, mean correct response latency, and mean 
incorrect latency.  Statistics were calculated using Statistical Package for the Social Sciences 
(SPSS) Version 21.  The MK-801 and SNP dose-response data was analyzed using a one-way 
repeated measures ANOVA.  Post-hoc analysis was performed with simple contrast tests, 
making comparisons only to saline.  Two-way repeated measures ANOVA were used to analyze 
all other data sets (MK-801+SNP).  One rat failed to complete any trials when treated with 4.0 
mg/kg of SNP and was removed from the SNP dose-response curve analysis and not used for 
other testing.  The final number of rats included in the analysis was 9 for the SNP dose-response 
curve.  Corrections for sphericity violations, as indicated by Mauchly’s test, were made using the 
Greenhouse-Geisser correction.  Partial η2 was calculated as a measure of effect size and 
represents the total variability in each dependent variable that can attributed to the intervention.  
Partial η2 values of 0.01, 0.06, and 0.14 are considered small, medium, and large effect sizes 
respectively.   
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2.5 Results 
2.5.1 MK-801 impaired TUNL performance in a dose-dependent manner 
 MK-801 (0.05, 0.075, 0.1 mg/kg) or saline was administered 25 minutes prior to TUNL 
testing.  A repeated measures ANOVA revealed a dose-dependent effect of the drug on several 
dependent variables. Overall accuracy was altered following MK-801 treatment (Fig 2A; 
F(3,27)=4.28, p=0.014, partial η2=0.322) with a post-hoc analysis identifying reduced 
performance following 0.1 mg/kg of MK-801 compared to saline treatment.  Trials were grouped 
according to their pattern separation.  MK-801 had an effect on large distance trials (Fig 2B; 
F(3,27)=3.83, p=0.021, partial η2=0.299), with 0.1 mg/kg of MK-801 impairing performance 
compared to saline.  Although MK-801 trended toward impairing accuracy on small distance 
trials, the effect was not significant (Fig 2B; p=0.058, partial η2=0.239).  The number of 
selection trials completed was unaffected by MK-801 (Fig 2C; p>0.05) but a main effect was 
observed for correction trials (Fig 2D; F(3,27)=4.13, p=0.016, partial η2=0.315) and total trials 
(Fig 2E; F(3,27)=3.39, p=0.032, partial η2=0.274).  Subsequent post-hoc analysis revealed 
significant increase in correction and total trials completed following 0.05 and 0.1 mg/kg of MK-
801 compared to saline treatments. Reward latency was altered following MK-801 treatment 
(Fig 2F; F(3,27)=6.59, p=0.002, partial η2=0.423) with post-hoc analysis revealing all MK-801 
treatments reduced latency compared to saline.  The time to make a correct selection did not vary 
among the treatments (Fig 2F; p>0.05).  MK-801 reduced incorrect latency (Fig 2F; 
F(3,27)=3.98, p=0.018, partial η2=0.307), with rats treated with 0.05 and 0.1 mg/kg of MK-801 
being significantly faster than saline. 
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Fig 2. Effects of MK-801 (0.05, 0.075, 0.1 mg/kg) on TUNL.  A. Accuracy as measured by the 
percentage of selection trials correctly completed.  B. Accuracy broken down according to the 
difficulty of pattern separation.  Separate repeated measures ANOVAs were completed for each 
pattern.  C. Number of unique trials completed by the rats. D. Number of correction trials 
completed by rats.  E. Sum of selection and correction trials completed by the rat.  F. Response 
latencies for reward collection, correct trials and incorrect trials.  Separate ANOVAs were used 
for each latency.  * p<0.05 between groups as indicated. 
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2.5.2 SNP impaired TUNL performance in a dose-dependent manner 
 SNP (0.5, 1.0, 2.0, 4.0 mg/kg) or saline were administered 25 minutes prior to TUNL task 
initiation.  SNP impaired performance on overall accuracy (Fig 3A; F(2.10, 16.81)=6.64, p 
=0.007, partial η2=0.454) with subsequent post-hoc analysis revealing a significant difference 
between saline and 4 mg/kg SNP treatments.  SNP did not alter performance on maximum 
distance trials (Fig 3B; p>0.05).  There was a main effect of SNP on minimum separation trial 
accuracy (3B; F(4,31)=4.67, p=0.004, partial η2=0.368) such that 4.0 mg/kg of SNP treatment 
impaired performance compared to saline treatment.  SNP reduced the number of selection trials 
completed (Fig 3C; F(1.10, 8.81)=15.98, p=0.003, partial η2=0.666) and post-hoc analysis 
identified fewer selection trials were completed following 4.0 mg/kg of SNP compared to saline 
treatment.  No significant effect of SNP was observed on correction trials (Fig 3D; p>0.05). SNP 
had a significant effect on the number of total trials completed (Fig 3E; F(1.28, 10.22)=12.33, 
p=0.004, partial η2=0.606).  Subsequent post-hoc analysis revealed a significantly fewer total 
trials were completed after 4.0 mg/kg of SNP compared to saline treatment.  Subsequent analysis 
demonstrated a main effect of SNP on reward latency (Fig 3F; F(1.90, 15.27)=10.38, p=0.002, 
partial η2=0.565) and correct latency (Fig 3F; F(2.06, 23.06)=5.56, p=0.014, partial η2=0.410) 
with a difference between saline and treatment with 2 mg/kg or 4 mg/kg of SNP on both.  SNP 
increased incorrect latency (Fig 3F; F(2.03, 16.22)=4.10, p=0.036, partial η2=0.339) with a 
significant difference between saline and 4 mg/kg SNP treatments.     
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 Fig 3. Effects of SNP (0.5, 1.0, 2.0, 4.0 mg/kg) on TUNL.  A. Accuracy as measured by the 
percentage of selection trials correctly completed.  B. Accuracy broken down according to the 
difficulty of pattern separation.  Separate repeated measures ANOVAs were completed for each 
pattern.  C. Number of unique trials completed by the rats. D. Number of correction trials 
completed by rats.  E. Sum of novel and correction trials completed by the rat.  F. Response 
latencies for reward collection, correct trials and incorrect trials.  Separate ANOVAs were used 
for each latency.  * p<0.05 between groups as indicated. 
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2.5.3 SNP improved pattern separation but failed to alleviate MK-801 impairments on the TUNL 
 task 
 MK-801 and SNP doses was chosen based on the collected dose-response curve 
performance data.  The 0.1 mg/kg dose of MK-801 was used because it produced the most robust 
impairment in TUNL task without increasing latency.  The 2.0 mg/kg dose of SNP was the 
highest tested dose that did not impair TUNL performance or dramatically increase latency.  The 
SNP (2.0 mg/kg) or saline was administered 5 minutes prior to MK-801 (0.05 mg/kg) or saline to 
observe whether SNP would rescue TUNL performance.  A 2 (MK-801, saline) by 2 (SNP, 
saline) repeated measures ANOVA revealed no significant interactions between MK-801 and 
SNP treatment on any of the variables (statistics not shown).  There was a main effect of MK-
801 (F(1,11)=15.63, p=0.002, partial η2=0.587) but not SNP (p>.05) on overall accuracy (Fig 
4A).  Trials were further divided according to working memory (2 s, 6 s) or pattern separation 
(large, small).  MK-801 impaired trials that contained a 2 s delay (Fig 4C; F(1,11)=7.21, 
p=0.021, partial η2=0.396), 6 s delay (Fig 4C; F(1,11)=14.36, p=0.003, partial η2=0.566), or 
large distances (Fig 4B; F(1,11)=26.83, p<0.001, partial η2=0.709) while SNP did not affect 
these variables (p>0.05).  In contrast, SNP trended toward improving performance during small 
distance trials (Fig 4B; p=0.058, partial η2=0.288) but MK-801 had no effect on these trials 
(p>.05).  MK-801 significantly reduced the number of selection trials completed by the rats (Fig 
4E; F(1,11)=11.47, p=0.006, partial η2=0.510).  Furthermore, MK-801 increased the number of 
correction trials (Fig 4F; F(1,11)=23.00, p=0.001, partial η2=0.676) and total trials (Fig 4G; 
F(1,11)=12.84, p=0.004, partial η2=0.539) completed.  SNP did not alter the number of selection 
trials or correction trials completed (Fig 4E,F; p > 0.05).  However, it is worth noting that SNP 
total trials trended toward being significantly increased (Fig 4G; p=0.053, partial η2=0.300).  
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Analysis of latency found that MK-801 decreased reward (Fig 4H; F(1,11)=9.73, p=0.010, 
partial η2=0.469), correct (Fig 4H; F(1,11)=14.41, p=0.003, partial η2=0.567), and incorrect 
latency (Fig 4H; F(1,11)=9.67, p=0.010, partial η2=0.468).  In contrast, SNP increased reward 
(Fig 4H; F(1,11)=35.35, p<0.001, partial η2=0.763) and incorrect latency (Fig 4H; F(1,11)=6.94, 
p=0.023, partial η2=0.387) but did not influence correct latency (Fig 4H; p>0.05).   
 To further investigate the effects of SNP on the TUNL task, trials were categorized into 
four groups based on their delay and pattern.  MK-801 significantly impaired performance at the 
6 s delay regardless of whether the separation was large (Fig 4D; F(1,11)=18.64, p=0.001, partial 
η2=0.629) or small (Fig 4D; F(1,11)=5.93, p=0.033, partial η2=0.350).  MK-801 also reduced 
accuracy on 2 s delay and large separation (Fig 4D; F(1,11)=10.60, p=0.008, partial η2=0.491) 
but not 2 s delay and small separation trials (p>0.05).  In contrast, SNP had no effect on trials 
with a 2 s delay and large separation, 6 s delay and small separation, or 6 s delay large separation 
but facilitated performance on trials with a 6 s delay and small separation (Fig 4D; F(1,11)=7.79, 
p=0.018, partial η2=0.414).   
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Fig 4. Effects of SNP (2.0 mg/kg) and MK-801 (0.1 mg/kg) on TUNL.  A. MK-801 significantly 
reduced accuracy, while SNP had no effect.  B.  MK-801 reduced accuracy when the stimuli had 
a large separation and had no effect when they were closer together.  SNP did not alter 
performance for large separations but facilitated performance for small separations (p=0.058).  
C.  MK-801 reduced the number of correct responses at the 2 s and 6 s delay, while SNP had no 
effect.  D. Trials were broken down according to separation and delay.  MK-801 impaired 
performance on 2 s delay and large separation, 6 s delay and large separation, and 6 s delay small 
separation trials.  SNP significantly improved performance on trials with a 2 s delay and small 
separation.  E. MK-801 reduced selection trials completed while SNP had no effect.  MK-801 
increased the number of correction (F) and total (G) trials completed while SNP did not change 
the number of completed trials.  H. MK-801 reduced reward, correct and incorrect latency while 
SNP increased reward and incorrect latency but did not affect correct latency in this sample.  * 
indicate a significant effect of MK-801 (p<0.05).  ^ indicate a significant effect of SNP (p<0.05). 
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2.5.4 SNP does not prevent MK-801-induced impairments in the TUNL task 
 Previous studies have examined the potential of SNP to prevent the cognitive 
impairments observed in NMDA dysfunction models of schizophrenia (Maia-de-Oliveira et al. 
2015b).  A previously published experiment using MK-801 in TUNL found that the 0.05 mg/kg 
dose of MK-801 was sufficient to reduce performance compared to saline, as higher doses led to 
high omission rates (Kumar et al. 2015a).  Our dose-response curve showed 0.05 mg/kg of MK-
801 was sufficient to change performance on correction trials, thus the lower dose was used in 
the following experiment.  SNP (5 mg/kg) or was administered 3 hours and 35 minutes prior to 
MK-801 (0.05 mg/kg) or saline and 4 h prior to TUNL task initiation.  No interactions were 
significant following a 2 (MK-801, saline) by 2 (SNP, saline) repeated measures ANOVA 
(statistics not shown).  MK-801 reduced overall accuracy on the TUNL task (Fig 5A; 
F(1,15)=10.14, p=0.006, partial η2=0.404) on the TUNL task.  The impairment was observed 
whether the delay was 2 s (Fig 5B; F(1,15)=7.75, p=0.014, partial η2=0.341) or 6 s (Fig 5B; 
F(1,15)=5.517, p=0.038, partial η2=0.256).  After grouping trials according to pattern separation, 
it was observed that MK-801 impaired performance on small distance trials (Fig 5B; 
F(1,15)=8.38, p=0.011, partial η2=0.359) but not large distance performance (Fig 5C; p=0.061, 
partial η2=0.215).  SNP did not influence overall, pattern separation, or delay accuracy (Fig 
5A,B,C; p>0.05).  As a result of the null effect of SNP on accuracy, an investigation of SNP 
following the categorization of trials according to working memory and pattern separation was 
not conducted. Neither SNP nor MK-801 influenced the number of selection trials the rat 
completed (Fig 5D; p>0.05).  However, MK-801 increased the number of correction trials (Fig 
5E; F(1,15)=18.38, p<0.001, partial η2=0.551) and total trials (Fig 5F; F(1,15)=40.65, p<0.001, 
partial η2=0.730) the rat completed.  There was no significant main effect of SNP on total trials 
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(Fig 5F; Fig p>.05) but the completion of fewer correction trials trended toward significance (Fig 
5E; p=0.063, partial η2=0.212).  MK-801 significantly reduced reward (Fig 5G; F(1,15)=18.35, 
p<0.001, partial η2=0.550), correct (Fig 5G; F(1,15)=26.78, p<0.001, partial η2=0.641), and 
incorrect latency times (Fig 5G; F(1,15)=38.31, p<0.001, partial η2=0.719).  SNP did not 
influence reward and correct latencies (Fig 5G; p>0.05) but significantly increased incorrect 
latency (Fig 5G; F(1,15)=8.70, p=0.010, partial η2=0.367). 
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Fig 5. Effects of SNP (5 mg/kg) when administered prior to MK-801 (0.05 mg/kg) on TUNL.  A. 
MK-801 significantly reduced performance on overall accuracy across all selection trials but 
SNP had no effect.  B. MK-801 impaired performance on small separation trials but did not 
influence performance on large separation trials.  SNP did not affect performance regardless of 
pattern separation.  C. MK-801 impaired performance on both delays but SNP had no effect on 
either.  D. Drug treatment did not affect the number of selection trials completed.  MK-801 but 
not SNP increased the number of correction (E) and total (F) trials completed.  G. MK-801 
reduced latency on reward, correct, and incorrect latencies while SNP only affected incorrect 
latency by increasing it.  * indicate a significant effect of MK-801 (p<0.05).  ^ indicate a 
significant effect of SNP (p<0.05).       
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2.6 Discussion 
 The cognitive symptoms of schizophrenia are not alleviated by conventional 
antipsychotics (Marder and Fenton 2004).  Recently, SNP has demonstrated promise as an 
adjunct treatment to reduce these symptoms, specifically reducing working memory impairments 
(Maia-de-Oliveira et al. 2015a).  In the current experiments, we examined the effects of SNP in 
the acute MK-801 model of schizophrenia within the TUNL task.  MK-801 (0.05 and 0.1 mg/kg) 
impaired TUNL performance by reducing accuracy and increasing the number of correction 
trials completed.  SNP did not attenuate (2.0 mg/kg) or prevent (5.0 mg/kg) MK-801-induced 
performance changes.  Interestingly, SNP independently improved accuracy on trials with small 
pattern separations.     
2.6.1 MK-801-induced disruption of TUNL 
 NMDA receptor dysfunction contributes to symptom manifestation in patients with 
schizophrenia (Adell et al. 2012; Coyle 2012).  In rodents, acute MK-801 treatment demonstrates 
face validity as a model of schizophrenia as its administration produces behavioral changes 
similar to those observed in the disease (Nestler and Hyman 2010).  The acute administration of 
MK-801 results in locomotor hyperactivity (Howland et al. 2012; Mahmood et al. 2016), reduced 
sociability (Morales and Spear 2014), and performance deficits on touchscreen-based (Kumar et 
al. 2015b; Kumar et al. 2015a; Lins et al. 2015; Lins and Howland 2016) and working memory 
(Homayoun et al. 2004; Galizio et al. 2012) tasks.  One published study has explored the changes 
following acute MK-801 (0.05 mg/kg) administration in the TUNL task (Kumar et al. 2015a).  In 
that study, working memory performance was assessed following 1 s and 20 s delays.  In the 
present study, delays with less variability (2 s and 6 s) were used in order to detect subtle 
changes in performance due to delay.  We observed that, regardless of delay, MK-801 (0.05 and 
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0.1 mg/kg) reduced overall accuracy compared to saline.  This suggests that the TUNL task is 
vulnerable to NMDA receptor antagonism regardless of working memory demand.  In Kumar et 
al. (2015), TUNL task accuracy following a 20 s was only examined using large pattern 
separations.  In contrast, the present study included large and small separations during both 
delays.  Overall, we observed that MK-801 (0.05 mg/kg) reduces performance on large and small 
separation trials.  Accuracy on most trials, with the exception of 2 s delay and small pattern 
separation, was impaired following MK-801 (0.1 mg/kg).  The present study is the first to 
analyze the effects of MK-801 on correction trials.  Previous studies utilizing touchscreen tasks 
in rodents have identified correction trials as a measure of perseveration (Lins et al. 2015; Lins 
and Howland 2016), a behavior frequently observed in patients with schizophrenia (Szoke et al. 
2008; Ortuño et al. 2009).  We observed MK-801 treatment increased the number of correction 
trials completed by the rats, suggesting MK-801 hindered the ability to inhibit incorrect response 
selection.  These findings replicate MK-801-induced perseveration in a variety of other rodent 
paradigms (Cohn et al. 1992; Tuplin et al. 2015; Lins et al. 2015).   
 Previous studies have reported that MK-801 (0.05 mg/kg) has no effect on latency 
although MK-801 (0.075 mg/kg) increases reward and correct latencies on the TUNL task 
(Kumar et al. 2015a).  We expanded the latency variables to include incorrect latency and our 
data show MK-801 (0.05 and 0.1 mg/kg) reduces reward, correct, and incorrect latencies.  This 
finding contrasts previously reported MK-801-induced increase in latency on the TUNL task 
(Kumar et al. 2015a).  Reduced latency may be indicative of increased impulsive behavior 
following acute MK-801 treatment.  Taken together, reduced latency and an increased number of 
total trials completed suggests performance impairments on the TUNL task were not due to 
impediment of the physical ability to perform the task.  Other studies have determined MK-801 
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does not impair visual perception at doses similar to those used here (Talpos et al. 2012), thus it 
is unlikely performance deterioration was a consequence of perceptual changes.  The present 
experiment suggests acute MK-801 administration in rodents is capable of reducing the ability to 
resolve spatial patterns and maintain information across a delay.  Acute MK-801 administration 
may also lead to increased perseverative behavior and impulsivity.  Our findings are similar to 
the performance impairments that would be expected in patients with schizophrenia, providing 
additional support for the face validity of the MK-801 model of schizophrenia (Mesholam-
Gately et al. 2009; Das et al. 2014).      
2.6.2 SNP did not block MK-801-induced impairments but improved pattern separation 
  There are no available antipsychotics to alleviate the cognitive symptoms of 
schizophrenia.  The lack of a positive control has limited the assessment of predictive validity in 
rodent models of schizophrenia, impeding the translatable development and evaluation of 
treatments for these symptoms (Markou et al. 2009).  However, when SNP was administered as 
an adjunct treatment to patients with schizophrenia, it reduced working memory impairments on 
the n-back task (Maia-de-Oliveira et al. 2015a).  Previous rodent studies have mirrored these 
findings as SNP reduces ketamine-induced cognitive deficits (Trevlopoulou et al. 2016).  In the 
present study, SNP neither prevented (Fig 4; 5.0 mg/kg; 3 h and 35 min prior to MK-801) nor 
rescued (Fig 3; 2.0 mg/kg; 5 min prior to MK-801) MK-801-induced impairments in the TUNL 
task.  Our findings fail to replicate previous reports of reduced cognitive impairments in patients 
(Maia-de-Oliveira et al. 2015a) and ketamine-treated rats (Trevlopoulou et al. 2016) following 
SNP, suggesting that acute MK-801 administration in the TUNL task may not be an appropriate 
paradigm to study the effects SNP in schizophrenia.  
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 To the best of our knowledge, this is the first study to explore the effect of SNP on 
pattern separation and perseverative behaviors.  When SNP (2 mg/kg) was administered 30 min 
prior to TUNL task initiation, accuracy on small separation trials increased.  Although the p-
value failed to meet the threshold for significance (p=0.058), our measure of effect size was large 
(η=0.288) suggesting the lack of significance may simply be a result of a small sample size.  
When accuracy during small separation trials accounted for delay, the facilitated pattern 
separation appeared to be driven by significantly improved performance during 2 s delays and 
small separation trials.  Similarly, the administration of SNP 4 h prior to the TUNL task trended 
toward reducing the number of correction trials (p=0.063, η=0.212), suggesting that SNP may 
reduce perseverative behavior (Lins et al. 2015).  Taken together, this study is the first to 
demonstrate SNP may have intrinsic properties that facilitate pattern separation and reduce 
perseveration.  Future research should further explore the effects of SNP in these realms of 
cognition.   
2.7 Conclusion 
 The results of this study indicate that acute MK-801 administration impairs performance 
on the TUNL task.  Treatment with SNP did not reduce MK-801-induced accuracy impairments, 
suggesting the strengths of the acute MK-801 model of schizophrenia may not be high predictive 
validity.  SNP trended toward improving pattern separation and reducing perseveration but future 
research is required to support this assertion.    
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3.0 GENERAL DISCUSSION 
 The effects of SNP on MK-801-induced impairments in the TUNL task were tested in the 
present study.  MK-801 dose-dependently impaired performance on working memory and 
pattern separation.  SNP did not prevent or rescue these impairments.  Interestingly, SNP did 
improve performance on trials with difficult to discriminate patterns.  This is the first study to 
explore the effects of SNP on pattern separation suggesting it may have intrinsic cognitive 
enhancing capabilities.  Taken together, these results suggest that SNP does not alleviate the 
working memory impairments produced by acute MK-801 administration in the TUNL task.      
 
3.1 MK-801-Induced Impairments 
 MK-801 is a non-competitive NMDA receptor antagonist that induces a physiological 
and behavioral state in rodents analogous to some aspects of schizophrenia (Moghaddam and 
Krystal 2012).  In our study, MK-801 reduced overall accuracy and detailed analysis showed that 
working memory and pattern separating abilities were impaired.  Further, MK-801 reduced 
latency measures and increased the number of correction trials completed, which may be 
indicative of impulsivity and perseveration respectively (Lins et al. 2015; Lins and Howland 
2016).  By antagonising NMDA receptors, MK-801 reduced NMDA receptor function.  Beyond 
the primary effects of MK-801 on NMDA receptors, this drug has secondary effects that mimic 
some of the GABAergic changes that occur in schizophrenia.  Specifically MK-801 
preferentially binds to NMDA receptors on fast-spiking PV+ interneurons, preventing the influx 
of calcium and reducing the inhibitory effects of these cells on glutamatergic pyramidal neurons 
(Lewis and Moghaddam 2006).              
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 PV+ interneurons make up about 25% of the interneurons within the PFC (Hashimoto et 
al. 2003), yet altered GABAergic function in schizophrenia appears to be relatively specific to 
this subset of neurons (Lewis et al. 2005).  The 67-kDa isoform of glutamate acid decarboxylase 
(GAD67), an enzyme involved in GABA synthesis, messenger ribonucleic acid (mRNA) levels 
are markedly reduced in the dlPFC of patients with schizophrenia (Guidotti et al. 2000; Kimoto 
et al. 2014).  This reduction is primarily localized to PV+ interneurons (Curley et al. 2011).  
Therefore, the reduced GABA neurotransmission in PV+ neurons is secondary to altered NMDA 
receptor function.  The alterations in patient GAD67 levels are not improved by long-term 
haloperidol treatment (Volk et al. 2000).  Further, antagonism of NMDA receptors may mirror 
working memory impairments observed in schizophrenia through downstream GABAergic 
changes.  Information maintenance across a delay is believed to depend upon the coordinated 
and sustained firing of prefrontal pyramidal neurons (Goldman-Rakic 1995).  This 
synchronization relies on normal GABA functioning and the activation of fast-spiking 
interneurons within the dlPFC during the delay phase of working memory tasks (Wilson et al. 
1994).  PFC interneurons have been implicated in mnemonic and sensory-motor working 
memory (Rao et al. 2000).  Further support for the role of GABA in working memory comes 
from pharmacological studies where infusion of a GABAA antagonist into the dlPFC in monkeys 
or the mPFC of rats impairs working memory performance (Sawaguchi et al. 1989; Auger and 
Floresco 2015).  In summary, reduced GABA neurotransmission in PV+ neurons is secondary to 
altered NMDA receptor function.  Therefore, NMDA receptor antagonists pose the potential to 
model schizophrenia by incorporating GABA and glutamate dysfunction of schizophrenia 
(Lewis and Moghaddam 2006).     
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3.2 Nitric Oxide, Sodium Nitroprusside, and Schizophrenia 
 The present study found that SNP, a nitric oxide donor, did not prevent or rescue MK-
801-induced performance impairments in the TUNL task.  This experiment did not replicate 
previous rodent or human studies that demonstrated SNP ability to reduce psychomimetic or 
symptom presentation respectively (Hallak et al. 2013; Maia-de-Oliveira et al. 2015a; Maia-de-
Oliveira et al. 2015b; Trevlopoulou et al. 2016).  There are several explanations for the 
differences between previous studies and the present one.  First, this was the first rodent 
experiment to measure the effects of SNP in the acute MK-801 model.  Previous research has 
chosen to use ketamine as non-competitive NMDA receptor antagonists (Maia-de-Oliveira et al. 
2015b; Trevlopoulou et al. 2016).  Although all bind to NMDA receptors, different NMDA 
receptor antagonists may have divergent effects on downstream messengers and transcripts, 
producing variable behavioral changes (de Bartolomeis et al. 2013; Hillhouse and Porter 2014).  
Further, the varying structures, potencies, and binding profiles of these drugs may contribute to 
the differing psychomimetic behaviors induced (Hevers et al. 2008).  Secondly, this was the first 
study using the TUNL task as a measure of working memory.  Previous studies have observed 
SNP restores novelty preference and recognition memory in rodents (Trevlopoulou et al. 2016). 
However, this is the first rodent task examining cognition following SNP treatment using an 
operant conditioning paradigm.  Lastly, this is the only study using Long Evans rats, while others 
have primarily used the Sprague Dawley strain.  Strain has been shown to influence learning and 
memory as well as NMDA receptor binding and distribution (Lei et al. 2009; Kumar et al. 
2015b).  All three of these factors should be considered in future studies.   
 Interestingly, we observed SNP improved performance on small separation trials.  The 
effect did not reach the threshold of statistical significance but this may be a power issue. 
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Following subsequent trial breakdown, it was observed that these improvements were specific to 
small separation trials with a short delay.  To the best of our knowledge, this is the first study to 
explore the effects of SNP on pattern separation in any context.  The mechanism underlying 
SNPs antipsychotic and cognitive properties are unknown.  This may have implications in 
multiple disease pathologies where reduced pattern separation is believed to lead to disrupted 
episodic memory, such as schizophrenia (Tamminga et al. 2010) and Alzheimer’s disease 
(Palmer and Good 2011).     
 Nitric oxide (NO) is produced by enzymes within the nitric oxide synthase (NOS) family.   
There are three types of NOS enzymes: endothelial, cytokine-inducible, and neuronal.  Neuronal 
NOS (nNOS), is widely expressed in the brain including the hippocampus and frontal cortex 
(Blum-Degen et al. 1999) and is of particular importance in the study of schizophrenia 
(Freudenberg et al. 2015).  This enzyme is calcium-calmodulin dependent and is localized within 
central and peripheral neurons.  nNOS is physically coupled to the NMDA receptor complex.  
This NMDA receptor-nNOS coupling is believed to increase the efficacy of nNOS in response to 
glutamate-induced calcium influx following NMDA activation (Nedvetsky et al. 2002).  This 
enzyme catalyzes the conversion of L-arginine to NO (Szabó 1996).   NO diffuses across lipid 
membranes and into the cellular cytosol where it is primarily received by guanylate cyclase 
(GC).  The majority of mechanisms, including vasodilation and the inhibition of platelet 
aggregation, are mediated by GC (Szabó 1996).  Linkage analysis, candidate gene and genome-
wide association studies have supported nNOS as a risk gene for schizophrenia (reviewed in 
(Freudenberg et al. 2015)).  Interestingly, schizophrenia patients homozygous for a single 
nucleotide polymorphism in the nNOS gene, rs6490121, have significantly worse working 
memory and verbal IQ than other genotype groups (Donohoe et al. 2009).   This polymorphism 
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has also been correlated with altered patterns of activation in schizophrenia patient PFC during 
spatial working memory tasks in fMRI (Rose et al. 2012) and EEG (O’Donoghue et al. 2012) 
studies.  Therefore, disturbed nNOS function may relate to the cognitive impairments of the 
disease and pharmacologically altering the NO-GC pathway may reduce cognitive symptoms of 
schizophrenia.   
 In patients, SNP treatment often occurs via titration at low doses to allow for the careful 
monitoring (Friederich and Butterworth 1995; Hottinger et al. 2014).  The metabolism of SNP 
results in cyanide anion production of cyanide anions (Cn-) (Bisset et al. 1981).  Administration 
of SNP at too large of a dose or too quick of an infusion rate can lead to cyanide toxicity, 
producing metabolic acidosis, CNS dysfunction and cardiovascular instability (Bisset et al. 
1981).  Previous rodent studies using non-competitive NMDA receptor antagonists, such as PCP 
and ketamine, have demonstrated a reversal of the behavioral changes that are induced by these 
drugs following SNP  (Bujas-Bobanovic et al. 2000a; Maia-de-Oliveira et al. 2015b; 
Trevlopoulou et al. 2016).  The precise mechanism that produces these behavioral changes is not 
clear.  N(G)-nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor, potentiates the PCP-
induced behavior and c-fos expression, reducing expression within the frontal cortex.  This 
suggests the involvement in the NO system in PCPs mechanism of action (Bujas-Bobanovic et 
al. 2000b).  The expression of c-fos, an immediate early gene, is indicative of a metabolically 
active neuronal population.  In contrast to saline, immunostaining identifies more predominant 
neuronal activation globally, with specifically high levels of increased expression in the cortical 
regions of the brain following PCP treatment.  2 mg/kg of SNP was sufficient to reduce the c-fos 
activation in the frontal cortex neurons and 6 mg/kg reduced overall expression of c-fos to levels 
not significantly different from saline+saline or SNP (2, 4, or 6)+saline treatments (Bujas-
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Bobanovic et al. 2000a).  PCP interacts with many other neurotransmitter systems, therefore 
other receptors and pathways may be involved in increased expression of c-fos.  This is 
supported by the c-fos expression not being symmetrical to the distribution of NMDA receptors, 
with low expression observed in the hippocampus and striatum.  However, the activation could 
be a consequence of reduced inhibitory tone in the brain due to the inactivation of GABA 
receptors (Bujas-Bobanovic et al. 2000a).   
 Several mechanisms relating to SNPs cognitive alleviating properties have been 
proposed.  One mechanism suggests that the alleviation in cognitive impairments is due to 
increased blood flow.  Vasodilation is induced by donated nitric oxide diffusing into vascular 
smooth muscle and activating guanylate cyclase directly.  This results in the production of cyclic 
guanosine monophosphate (cGMP) which inhibits calcium from entering the cell and may 
increase the reuptake of calcium into the smooth endoplasmic reticulum (Friederich and 
Butterworth 1995).  The second mechanism suggests that SNP improves cognition through its 
activation of cyclic guanosine monophosphate.  The nNOS converts L-arginine to NO, thus 
increased levels of L-arginine may increase nNOS dysfunctional in schizophrenia.  However, the 
administration of L-arginine does not interfere with PCP-induced behavioral effects nor does it 
alter PCP-induced cfos expression (Bujas-Bobanovic et al. 2000a).  But this could be due to NO 
production not being dependent upon the extracellular substrate (Szabó 1996).  Thus, it is 
proposed that SNP blocks PCP effects by bypassing nNOS and activating the NO-guanylyl 
cyclase signalling pathway.  Another prediction is that SNP works through its mediation of tissue 
plasminogen factor release by endothelial cells (Hoirisch-Clapauch and Nardi 2015).  Ultimately, 
the mechanism that allows the amelioration of schizophrenic symptoms remains largely 
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unknown and future research should aim at understanding this pathway and verifying previous 
pilot study findings (Maia-de-Oliveira et al. 2015a).    
 There are several ways to direct future research related to this thesis.  One initial 
objective may be to expand this methodology by incorporating changes that increase the 
alignment between our study and human pilot studies of SNP.  This may be done by injecting an 
antipsychotic in conjunction to SNP or using a pump instead of a single injection to administer 
the SNP dose over a longer period of time (Hallak et al. 2013; Maia-de-Oliveira et al. 2015a).  In 
addition, future studies may investigate the predictive validity of the MK-801 model. Our study 
was the first to explore the effects of SNP in the MK-801 model of schizophrenia in a working 
memory task in rodents.  This novelty makes it difficult to determine whether our null findings 
were a consequence of the model of schizophrenia chosen or the task utilized.  Therefore, it 
would be beneficial to take a rodent behavioral paradigm that has been shown the positive effects 
of SNP (e.g., ketamine in the novel object recognition task) and replace ketamine with MK-801 
(Trevlopoulou et al. 2016).  If SNP reduced the recognition memory impairments induced by 
MK-801 treatment, it would suggest the TUNL task may not be appropriate in the study of SNP.  
Similarly, it would be beneficial to use ketamine as the model of schizophrenia in the TUNL task 
because SNP has been effective in reducing other cognitive impairments in this model 
(Kandratavicius et al. 2015; Trevlopoulou et al. 2016).  If SNP was able to alleviate ketamine-
induced TUNL task impairments, ketamine treatment may hold greater predictive validity than 
MK-801 as a model of schizophrenia.  
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3.3 General Conclusion 
 This thesis presents novel findings regarding the treatment of cognitive deficits of 
schizophrenia within a rodent model.  The data demonstrates the efficacy of acute MK-801 
treatment in inducing robust working memory impairments, similar to those observed in patients 
with schizophrenia.  Previous rodent and patient studies have demonstrated SNP’s capacity to 
alleviate cognitive impairments but this was not replicated in our experiment.  This thesis is the 
first to suggest SNP may improve pattern separation.  These findings provide valuable insight 
into the face and predictive validity of the MK-801 model within the TUNL task.      
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